Logo image
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
期刊文章   開放取用(OA)   同儕審查

Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy

Shunsuke Chikuma, Mitsuhiro Kanamori, Setsuko Mise-OmataAkihiko Yoshimura
Cancer Science, 卷.108(4), 頁碼.574-580
04/2017
PMID: 28188673

摘要

Immune checkpoint JAK-STAT kinase inhibitory region suppressors of cytokine signaling T cell Oncology Cancer Research
Inhibition of immune checkpoint molecules, PD-1 and CTLA4, has been shown to be a promising cancer treatment. PD-1 and CTLA4 inhibit TCR and co-stimulatory signals. The third T cell activation signal represents the signals from the cytokine receptors. The cytokine interferon-γ (IFNγ) plays an important role in anti-tumor immunity by activating cytotoxic T cells (CTLs). Most cytokines use the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, and the suppressors of cytokine signaling (SOCS) family of proteins are major negative regulators of the JAK/STAT pathway. Among SOCS proteins, CIS, SOCS1, and SOCS3 proteins can be considered the third immunocheckpoint molecules since they regulate cytokine signals that control the polarization of CD4 + T cells and the maturation of CD8 + T cells. This review summarizes recent progress on CIS, SOCS1, and SOCS3 in terms of their anti-tumor immunity and potential applications.

檔案與連結 (1)

url
https://doi.org/10.1111/cas.13194檢視
已出版(紀錄版本) 開放

相關連結

指標

1 檢視次數

詳細資料

Logo image